{"id":1071,"date":"2022-06-19T17:44:06","date_gmt":"2022-06-19T17:44:06","guid":{"rendered":"http:\/\/sylentis.com\/?page_id=1071"},"modified":"2022-07-11T08:26:59","modified_gmt":"2022-07-11T08:26:59","slug":"productos-syl1801","status":"publish","type":"page","link":"https:\/\/sylentis.com\/es\/productos-syl1801\/","title":{"rendered":"Productos SYL1801"},"content":{"rendered":"\n\t<section class=\"section\" id=\"section_1489918204\">\n\t\t<div class=\"section-bg fill\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1500\" height=\"472\" src=\"https:\/\/sylentis.com\/wp-content\/uploads\/2022\/05\/Sylentis_b_008.jpg\" class=\"bg attachment- size-\" alt=\"\" \/>\t\t\t\t\t\t\n\t\t\t\n\n\t\t<\/div>\n\n\t\t\n\n\t\t<div class=\"section-content relative\">\n\t\t\t\n<div class=\"row\"  id=\"row-1143129009\">\n\n\t<div id=\"col-1530196057\" class=\"col medium-4 small-12 large-4\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-539703143\" class=\"col medium-3 small-12 large-3\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-1498773825\" class=\"col medium-4 small-12 large-4\"  >\n\t\t\t\t<div class=\"col-inner\" style=\"background-color:rgba(255, 255, 255, 0.797);\" >\n\t\t\t\n\t\t\t\n\t<div id=\"text-4247649730\" class=\"text\">\n\t\t\n<p class=\"thin-font\"><span style=\"color: #99cc00; font-size: 35%;\">NUESTRA CIENCIA<\/span><br \/><span style=\"font-size: 120%;\"><strong>Pipeline de Sylentis<\/strong><\/span><\/p>\n\t\t\n<style>\n#text-4247649730 {\n  font-size: 2.5rem;\n  line-height: 1.15;\n}\n<\/style>\n\t<\/div>\n\t\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1498773825 > .col-inner {\n  padding: 13px 0px 0px 16px;\n  border-radius: 11px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n\t\t<\/div>\n\n\t\t\n<style>\n#section_1489918204 {\n  padding-top: 0px;\n  padding-bottom: 0px;\n  min-height: 465px;\n}\n<\/style>\n\t<\/section>\n\t\n\n\t<section class=\"section\" id=\"section_103887872\">\n\t\t<div class=\"section-bg fill\" >\n\t\t\t\t\t\t\t\t\t\n\t\t\t\n\n\t\t<\/div>\n\n\t\t\n\n\t\t<div class=\"section-content relative\">\n\t\t\t\n<div class=\"row row-collapse row-full-width align-middle\"  id=\"row-229628339\">\n\n\t<div id=\"col-1365703727\" class=\"col medium-12 large-6\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"gap-1925317202\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1925317202 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"text-467781214\" class=\"text\">\n\t\t\n<h3>SYL1801<\/h3>\n\t\t\n<style>\n#text-467781214 {\n  font-size: 2rem;\n  line-height: 1;\n}\n<\/style>\n\t<\/div>\n\t\n<p>SYL1801 es un siRNA qu\u00edmicamente modificado y dise\u00f1ado mediante SirFinder\u2122, propiedad de Sylentis, en fase II de investigaci\u00f3n cl\u00ednica para la prevenci\u00f3n y\/o el control de la progresi\u00f3n de la <strong>degeneraci\u00f3n macular asociada a la edad<\/strong> (DMAE) de tipo h\u00fameda.<\/p>\n<p>SYL1801 se administra en forma de colirio en soluci\u00f3n (gotas oculares) para disminuir a nivel transcripcional la expresi\u00f3n de Nrarp, una diana distinta a aquellas contra las que se dirigen las terapias antiangiog\u00e9nicas habituales basadas en agentes anti-VEGF.<\/p>\n<p>SYL1801 inhibe la s\u00edntesis de Nrarp, que juega un papel importante en el control de la formaci\u00f3n de nuevos vasos sangu\u00edneos en la retina.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1365703727 > .col-inner {\n  padding: 20px 20px 20px 20px;\n  margin: 0px 0px 77px 0px;\n}\n@media (min-width:550px) {\n  #col-1365703727 > .col-inner {\n    padding: 30px 50px 40px 50px;\n  }\n}\n@media (min-width:850px) {\n  #col-1365703727 > .col-inner {\n    padding: 0px 20% 0px 15%;\n  }\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1872926935\" class=\"col medium-12 large-6\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n  <div class=\"banner has-hover\" id=\"banner-1840312797\">\n          <div class=\"banner-inner fill\">\n        <div class=\"banner-bg fill\" >\n            <img loading=\"lazy\" decoding=\"async\" width=\"1020\" height=\"530\" src=\"https:\/\/sylentis.com\/wp-content\/uploads\/2022\/07\/Sylentis_SYL1801-1024x532.jpg\" class=\"bg attachment-large size-large\" alt=\"\" \/>                                    \n                    <\/div>\n\t\t\n        <div class=\"banner-layers container\">\n            <div class=\"fill banner-link\"><\/div>            \n        <\/div>\n      <\/div>\n\n            \n<style>\n#banner-1840312797 {\n  padding-top: 300px;\n  background-color: rgba(255, 255, 255, 0);\n}\n#banner-1840312797 .banner-bg img {\n  object-position: 45% 22%;\n}\n@media (min-width:550px) {\n  #banner-1840312797 {\n    padding-top: 500px;\n  }\n}\n@media (min-width:850px) {\n  #banner-1840312797 {\n    padding-top: 600px;\n  }\n}\n<\/style>\n  <\/div>\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n<\/div>\n\t<div id=\"gap-138361908\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-138361908 {\n  padding-top: 69px;\n}\n<\/style>\n\t<\/div>\n\t\n\t\t<\/div>\n\n\t\t\n<style>\n#section_103887872 {\n  padding-top: 0px;\n  padding-bottom: 0px;\n}\n<\/style>\n\t<\/section>\n\t\n\n\t<section class=\"section dark has-mask mask-arrow\" id=\"section_710976044\">\n\t\t<div class=\"section-bg fill\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"940\" height=\"390\" src=\"https:\/\/sylentis.com\/wp-content\/uploads\/2022\/05\/degeneracion-macular-asociada-edad.jpg\" class=\"bg attachment- size-\" alt=\"\" \/>\t\t\t\t\t\t<div class=\"section-bg-overlay absolute fill\"><\/div>\n\t\t\t\n\t<div class=\"is-border\"\n\t\tstyle=\"border-color:rgb(235, 235, 235);border-width:0px 0px 0px 0px;margin:0px 0px 0px 0px;\">\n\t<\/div>\n\n\t\t<\/div>\n\n\t\t\n\n\t\t<div class=\"section-content relative\">\n\t\t\t\n<div class=\"row\"  id=\"row-1297034123\">\n\n\t<div id=\"col-997997782\" class=\"col medium-4 small-12 large-4\"  >\n\t\t\t\t<div class=\"col-inner text-shadow-2\"  >\n\t\t\t\n\t\t\t\n<p>\u00a0<\/p>\n<h2 class=\"uppercase\">APLICACI\u00d3N:<\/h2>\n<h2 class=\"uppercase\">DEGENERACI\u00d3N MACULAR<\/h2>\n<p>La<strong> degeneraci\u00f3n macular<\/strong> es una afecci\u00f3n degenerativa de una parte central de la retina conocida como m\u00e1cula, que es la responsable de la visi\u00f3n central. Es decir, esta zona del ojo permite realizar tareas de visi\u00f3n fina como reconocer caras, leer o coser.<\/p>\n<p>\u00a0<\/p>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-547340278\" class=\"col medium-4 small-12 large-4\"  >\n\t\t\t\t<div class=\"col-inner text-shadow-2\"  >\n\t\t\t\n\t\t\t\n<ul>\n<li>La DMAE es la principal causa de <strong>discapacidad visual<\/strong> irreversible en la poblaci\u00f3n de edad avanzada de los pa\u00edses desarrollados.<\/li>\n<li>Actualmente el <strong>tratamiento de la DMAE<\/strong> implica la inyecci\u00f3n intraocular peri\u00f3dica de f\u00e1rmacos antiangiog\u00e9nicos.<\/li>\n<li>El desarrollo de f\u00e1rmacos que se administren por v\u00edas no invasivas es una necesidad m\u00e9dica a\u00fan no cubierta para este tipo de pacientes.<\/li>\n<\/ul>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-1348687448\" class=\"col medium-4 small-12 large-4\"  >\n\t\t\t\t<div class=\"col-inner text-shadow-2\"  >\n\t\t\t\n\t\t\t\n<p>La visi\u00f3n borrosa, la aparici\u00f3n de puntos negros en la zona central del campo visual y la percepci\u00f3n distorsionada u ondulada de l\u00edneas rectas son los principales s\u00edntomas de esta enfermedad.<\/p>\n<p>A d\u00eda de hoy la <strong>DMAE<\/strong> se puede controlar mediante el uso de f\u00e1rmacos antiangiog\u00e9nicos que se administran mediante inyecciones intraoculares peri\u00f3dicas. El desarrollo de f\u00e1rmacos administrados en gotas supondr\u00eda una mejora sustancial en la calidad de vida de los pacientes.<\/p>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n<\/div>\n\t\t<\/div>\n\n\t\t\n<style>\n#section_710976044 {\n  padding-top: 59px;\n  padding-bottom: 59px;\n  min-height: 300px;\n  background-color: rgb(0, 0, 0);\n}\n#section_710976044 .section-bg-overlay {\n  background-color: rgba(0, 0, 0, 0.733);\n}\n<\/style>\n\t<\/section>\n\t\n\t<div id=\"gap-834491563\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-834491563 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-blank.php","meta":{"footnotes":""},"class_list":["post-1071","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/sylentis.com\/es\/wp-json\/wp\/v2\/pages\/1071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sylentis.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sylentis.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sylentis.com\/es\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sylentis.com\/es\/wp-json\/wp\/v2\/comments?post=1071"}],"version-history":[{"count":8,"href":"https:\/\/sylentis.com\/es\/wp-json\/wp\/v2\/pages\/1071\/revisions"}],"predecessor-version":[{"id":2088,"href":"https:\/\/sylentis.com\/es\/wp-json\/wp\/v2\/pages\/1071\/revisions\/2088"}],"wp:attachment":[{"href":"https:\/\/sylentis.com\/es\/wp-json\/wp\/v2\/media?parent=1071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}